Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

by Agerbaek, Mads , Qureshi, Anila , Tupikowski, Krzysztof , Unsal-Kacmaz, Keziban , Schenker, Michael , Koon, Henry B , Fischer, Bruce S , Gschwend, Jürgen E , Bajorin, Dean F , Gajate, Pablo , Milowsky, Matthew I , Valderrama, Begoña P , Broughton, Edward , Tomita, Yoshihiko , McDermott, Ray , Shariat, Shahrokh F , Enting, Deborah , Peer, Avivit , Galsky, Matthew D , Toms, Laurence , Bamias, Aristotelis , Ye, Dingwei , Park, Se Hoon , Lebret, Thierry , Nosov, Alexander , Neif Antonio, João , Zardavas, Dimitrios , Witjes, J. Alfred , Collette, Sandra

in Adjuvants / Adult / Adverse events / Aged / Aged, 80 and over / Antineoplastic Agents, Immunological - adverse effects / Antineoplastic Agents, Immunological - therapeutic use / B7-H1 Antigen - metabolism / Bladder / Bladder cancer / Cancer therapies / Carcinoma, Transitional Cell - drug therapy / Carcinoma, Transitional Cell - pathology / Carcinoma, Transitional Cell - surgery / Chemotherapy / Chemotherapy, Adjuvant / Cisplatin / Death / Disease-Free Survival / Double-Blind Method / Female / Humans / Immunotherapy / Intention to Treat Analysis / Invasiveness / Life Sciences / Male / Metastasis / Middle Aged / Monoclonal antibodies / Neoplasm Invasiveness / Neoplasm Staging / Nivolumab - adverse effects / Nivolumab - therapeutic use / Patients / PD-L1 protein / Placebos / Placebos - therapeutic use / Pneumonitis / Population / Quality of Life / Questionnaires / Surgery / Survival / Targeted cancer therapy / Tumors / Urinary Bladder Neoplasms - drug therapy / Urinary Bladder Neoplasms - pathology / Urinary Bladder Neoplasms - surgery / Urothelial carcinoma

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

2021

Confirm

Do you wish to request the book?

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

Agerbaek, Mads,

Qureshi, Anila,

Tupikowski, Krzysztof,

Unsal-Kacmaz, Keziban,

Schenker, Michael,

Koon, Henry B,

Fischer, Bruce S,

Gschwend, Jürgen E,

Bajorin, Dean F,

Gajate, Pablo,

Milowsky, Matthew I,

Valderrama, Begoña P,

Broughton, Edward,

Tomita, Yoshihiko,

McDermott, Ray,

Shariat, Shahrokh F,

Enting, Deborah,

Peer, Avivit,

Galsky, Matthew D,

Toms, Laurence,

Bamias, Aristotelis,

Ye, Dingwei,

Park, Se Hoon,

Lebret, Thierry,

Nosov, Alexander,

Neif Antonio, João,

Zardavas, Dimitrios,

Witjes, J. Alfred,

Collette, Sandra

2021

Overview

In a prospective, randomized trial involving patients with urothelial carcinoma who had undergone radical surgery, adjuvant nivolumab was compared with placebo. The median disease-free survival was 20.8 months with nivolumab and 10.8 months with placebo. Treatment-related adverse events of grade 3 or higher were noted in 17.9% of patients in the nivolumab group.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adjuvants

/ Adult

/ Adverse events

/ Aged

/ Aged, 80 and over

/ Antineoplastic Agents, Immunological - adverse effects

/ Antineoplastic Agents, Immunological - therapeutic use